Equity Profile

GKOS

Glaukos Corporation

Health CareHealth Care Equipment$11.2B

Jul29Wed

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Glaukos Corporation (GKOS) operates in the health care sector, focusing on innovative medical devices for treating eye diseases, particularly glaucoma. As the demand for advanced health care solutions continues to grow, Glaukos plays a crucial role in improving patient outcomes through its cutting-edge technologies.

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and financial health, which investors will closely watch.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and product adoption.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

GKOS Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+18.24%

Avg Stock Reaction

-0.98%

Last Quarter Recap

In Q1-2026, Glaukos reported an EPS of -$0.18, outperforming expectations by 39.6%. However, the stock fell by 2.23% the following day, indicating mixed market sentiment.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, the market is cautious ahead of Glaukos' earnings report, especially given the company's recent performance and lack of guidance.

Bull Case

Optimistically, if Glaukos can demonstrate strong revenue growth and continued improvement in EPS, it could signal a turnaround and boost investor confidence.

Bear Case

Conversely, if the company fails to meet expectations or provides weak guidance, it could lead to further declines in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the EPS for Q2-2026?

Given the recent EPS surprises, the market will closely evaluate if Glaukos can continue this trend or if it will fall short.

How is revenue trending compared to previous quarters?

Revenue growth is critical for assessing the company's market position and future prospects, especially in a competitive landscape.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Glaukos' ability to leverage its recent innovations for revenue growth, especially given the strong EPS surprises in the last quarters.

Supporting Evidence

Glaukos has consistently beaten EPS estimates, suggesting stronger operational performance than anticipated.

The options market is pricing in a larger move than historical averages, indicating that investors expect significant news.

The company's focus on innovative solutions could drive higher adoption rates, contrary to conservative market expectations.

Key Risk

If Glaukos reports an EPS better than -$0.10, it could challenge the current cautious outlook.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around whether Glaukos can maintain its momentum in profitability and revenue growth.

Bull Confirmed If

An EPS of -$0.10 or better would confirm the bull case and indicate strong operational performance.

Bear Confirmed If

An EPS worse than -$0.20 would confirm the bear case, signaling ongoing challenges.

Pre-Earnings Positioning

Options Market

Implied Move

±7.87%

Historical Avg

±1.2%

Pricing rich

The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings report.

Options are pricing ±7.9% while GKOS has averaged ±1.2% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

81.7%

Calls (15K)P/C Ratio: 0.39Puts (400)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Glaukos beats expectations, history suggests the stock could rise by around 1.17% on the first day, confirming positive momentum.

In-Line / Cautious

If results are in line but cautious commentary is provided, the stock may see muted movement, reflecting ongoing investor uncertainty.

Miss

A miss could lead to a decline of approximately 2.59%, as seen in past quarters, which would heighten concerns about the company's growth trajectory.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches and their expected impact on revenue.
2Details on market share changes in the glaucoma treatment space.
3Insights into cost management strategies and their effect on profitability.
4Comments on competitive pressures and how Glaukos plans to address them.
5Any guidance on future earnings expectations and strategic initiatives.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Jul27

DYNBMO

Dyne Therapeutics, Inc.

PreviewView

Jul27

ARLPBMO

Company Snapshot

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and financial health, which investors will closely watch.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and product adoption.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

GKOS Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+18.24%

Avg Stock Reaction

-0.98%

Last Quarter Recap

In Q1-2026, Glaukos reported an EPS of -$0.18, outperforming expectations by 39.6%. However, the stock fell by 2.23% the following day, indicating mixed market sentiment.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, the market is cautious ahead of Glaukos' earnings report, especially given the company's recent performance and lack of guidance.

Bull Case

Optimistically, if Glaukos can demonstrate strong revenue growth and continued improvement in EPS, it could signal a turnaround and boost investor confidence.

Bear Case

Conversely, if the company fails to meet expectations or provides weak guidance, it could lead to further declines in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the EPS for Q2-2026?

Given the recent EPS surprises, the market will closely evaluate if Glaukos can continue this trend or if it will fall short.

How is revenue trending compared to previous quarters?

Revenue growth is critical for assessing the company's market position and future prospects, especially in a competitive landscape.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Glaukos' ability to leverage its recent innovations for revenue growth, especially given the strong EPS surprises in the last quarters.

Supporting Evidence

Glaukos has consistently beaten EPS estimates, suggesting stronger operational performance than anticipated.

The options market is pricing in a larger move than historical averages, indicating that investors expect significant news.

The company's focus on innovative solutions could drive higher adoption rates, contrary to conservative market expectations.

Key Risk

If Glaukos reports an EPS better than -$0.10, it could challenge the current cautious outlook.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around whether Glaukos can maintain its momentum in profitability and revenue growth.

Bull Confirmed If

An EPS of -$0.10 or better would confirm the bull case and indicate strong operational performance.

Bear Confirmed If

An EPS worse than -$0.20 would confirm the bear case, signaling ongoing challenges.

Pre-Earnings Positioning

Options Market

Implied Move

±7.87%

Historical Avg

±1.2%

Pricing rich

The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings report.

Options are pricing ±7.9% while GKOS has averaged ±1.2% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

81.7%

Calls (15K)P/C Ratio: 0.39Puts (400)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Glaukos beats expectations, history suggests the stock could rise by around 1.17% on the first day, confirming positive momentum.

In-Line / Cautious

If results are in line but cautious commentary is provided, the stock may see muted movement, reflecting ongoing investor uncertainty.

Miss

A miss could lead to a decline of approximately 2.59%, as seen in past quarters, which would heighten concerns about the company's growth trajectory.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches and their expected impact on revenue.
2Details on market share changes in the glaucoma treatment space.
3Insights into cost management strategies and their effect on profitability.
4Comments on competitive pressures and how Glaukos plans to address them.
5Any guidance on future earnings expectations and strategic initiatives.